Indoximod as an Active IDO Pathway Inhibitor in Melanoma

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.

In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.

During a Targeted Oncology™ Case-Based Roundtable™ event, Anna C. Pavlick, DO, MSc, MBA, BSN, discussed first-line therapy for a patient with metastatic melanoma.